Retatrutide is still in clinical trials, yet people are discussing using it online. A new analysis takes a first systematic look at the side effects they describe.
Recap by typeshit. Post by Facebook on Facebook.
She walks through the phase 3 data, including knee osteoarthritis results, and explains why she calls online reta vials a gamble.
In a Healio Eye-Mail brief, she gives her view on a review of a possible link between GLP-1 medications and NAION, a type of optic nerve damage.
The Atlanta Journal-Constitution looks at how an unapproved weight loss drug is being sold through an underground market across Georgia.
The AJC found clinics in Georgia promoting and dispensing copies of retatrutide, a drug that has not been approved. Tap through for how they are getting away with it.
Bikman says the added glucagon receptor push raises energy use and liver fat burning, and points to 24.2% weight loss on 12 mg in phase 2.
9:08
Archibald takes on a common question about low retatrutide doses and the drug's glucagon action. His view, not settled science, and retatrutide is still unapproved.
Loading…